Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Respiratory virus vaccines. VII. Field evaluation of respiratory syncytial, parainfluenza 1, 2, 3, and Mycoplasma pneumoniae vaccines, 1965 to 1966.

× No keyword cloud information.

10 in total

1. Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.

Authors: Gertrud U Radu; Hayat Caidi; Congrong Miao; Ralph A Tripp; Larry J Anderson; Lia M Haynes
Journal: J Virol Date: 2010-06-30 Impact factor: 5.103

2. Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P.

Authors: Lia M Haynes; Les P Jones; Albert Barskey; Larry J Anderson; Ralph A Tripp
Journal: J Virol Date: 2003-09 Impact factor: 5.103

3. Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4.

Authors: Guillaume B E Stewart-Jones; Gwo-Yu Chuang; Kai Xu; Tongqing Zhou; Priyamvada Acharya; Yaroslav Tsybovsky; Li Ou; Baoshan Zhang; Blanca Fernandez-Rodriguez; Valentina Gilardi; Chiara Silacci-Fregni; Martina Beltramello; Ulrich Baxa; Aliaksandr Druz; Wing-Pui Kong; Paul V Thomas; Yongping Yang; Kathryn E Foulds; John-Paul Todd; Hui Wei; Andres M Salazar; Diana G Scorpio; Bridget Carragher; Clinton S Potter; Davide Corti; John R Mascola; Antonio Lanzavecchia; Peter D Kwong
Journal: Proc Natl Acad Sci U S A Date: 2018-11-12 Impact factor: 11.205

Respiratory virus vaccines. VII. Field evaluation of respiratory syncytial, parainfluenza 1, 2, 3, and Mycoplasma pneumoniae vaccines, 1965 to 1966.

1. Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.

2. Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P.

3. Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4.

4. Evolution of proteomics technologies for understanding respiratory syncytial virus pathogenesis.

Review 5. Respiratory viral infections in the elderly.

Review 6. Immunopathology of RSV: An Updated Review.

Review 7. Priorities for developing respiratory syncytial virus vaccines in different target populations.

8. RSV vaccine-enhanced disease is orchestrated by the combined actions of distinct CD4 T cell subsets.

9. Vaccination against SARS-CoV-2 and disease enhancement - knowns and unknowns.

Review 10. Applying Immune Instincts and Maternal Intelligence from Comparative Microbiology to COVID-19.